Literature DB >> 12612887

High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients.

W Saeger1, M Fassnacht, R Chita, G Prager, C Nies, K Lorenz, E Bärlehner, D Simon, B Niederle, F Beuschlein, B Allolio, M Reincke.   

Abstract

Incidentally detected adrenal tumors are a common finding during abdominal ultrasonography, computed tomography, and magnetic resonance imaging. Although most of these lesions are benign adenomas, adrenocortical carcinomas and metastases constitute 5% to 10% of all tumors. Adrenal biopsy may be helpful, but its diagnostic value is controversial and disputed, and prospective studies have not yet been performed. Therefore, the diagnostic accuracy of adrenal core biopsy was evaluated in a prospective multicenter study involving 8 surgical centers in Germany and Austria. A total of 220 biopsies from surgical specimens of the adrenal gland were punctured in an ex vivo approach and processed for pathohistologic diagnosis using paraffin sections, routine staining, and immunohistochemistry (keratin KL1, vimentin, S100 protein, chromogranin A, synaptophysin, neuron-specific enolase, D11, MiB-1, and p53 protein). The evaluating pathologist was blinded for clinical data from the patients. A total of 89 adrenal adenomas (40.5%), 22 adrenal carcinomas (10.0%), 55 pheochromocytomas (25.0%), 15 metastases (6.8%), 16 adrenal hyperplasias (7.2%), and 23 other tumors (10.5%) were studied. Nine cases were excluded due to incomplete data (n = 2) or insufficient biopsy specimen (n = 7). In the remaining 211 tumors, compared with the final diagnoses of the surgical specimen, bioptic diagnoses were absolutely correct in 76.8% of the cases, nearly correct in 13.2% of the cases, and incorrect in 10% of the cases. Pheochromocytomas were correctly diagnosed in 96% of the cases, cortical adenomas were correctly or nearly correctly reported in 91% of the cases, cortical carcinomas were correctly or nearly correctly reported in 76% of the cases, and metastases were correctly or nearly correctly reported in 77% of the cases. Of the 39 malignant lesions, only 4 were misclassified, 2 as benign and 2 as possibly malignant. This resulted in an overall sensitivity for malignancy of 94.6% and specificity of 95.3%. Our findings suggest that adrenal core biopsy is a useful method for identifying and classifying adrenal tumorous lesions if sufficient biopsy specimens can be obtained. However, in clinical practice it remains to be shown whether the benefits of biopsy outweigh the risks of the procedure. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12612887     DOI: 10.1053/hupa.2003.24

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

1.  Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation.

Authors:  G Tirabassi; B Kola; M Ferretti; R Papa; T Mancini; F Mantero; M Scarpelli; M Boscaro; G Arnaldi
Journal:  J Endocrinol Invest       Date:  2011-10-04       Impact factor: 4.256

2.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 3.  Interventional radiology of the adrenal glands: current status.

Authors:  Anna Maria Ierardi; Mario Petrillo; Francesca Patella; Pierpaolo Biondetti; Enrico Maria Fumarola; Salvatore Alessio Angileri; Filippo Pesapane; Antonio Pinto; Gianlorenzo Dionigi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

Review 4.  The indeterminate adrenal mass.

Authors:  Barney Harrison
Journal:  Langenbecks Arch Surg       Date:  2011-09-23       Impact factor: 3.445

Review 5.  Surgical management of adrenal metastases.

Authors:  Juan J Sancho; Frédéric Triponez; Xavier Montet; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2011-12-16       Impact factor: 3.445

Review 6.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

Review 7.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

Review 8.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

9.  Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.

Authors:  Andrew R Williams; Gary D Hammer; Tobias Else
Journal:  Eur J Endocrinol       Date:  2014-06       Impact factor: 6.664

Review 10.  The role of regulated necrosis in endocrine diseases.

Authors:  Wulf Tonnus; Alexia Belavgeni; Felix Beuschlein; Graeme Eisenhofer; Martin Fassnacht; Matthias Kroiss; Nils P Krone; Martin Reincke; Stefan R Bornstein; Andreas Linkermann
Journal:  Nat Rev Endocrinol       Date:  2021-06-16       Impact factor: 47.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.